Search

Your search keyword '"Ledoux-Pilon A"' showing total 10 results
Start Over Author "Ledoux-Pilon A" Topic female
10 results on '"Ledoux-Pilon A"'

1. Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome

Author

Luis Veloza, Doriane Cavalieri, Edoardo Missiaglia, Albane Ledoux-Pilon, Bettina Bisig, Bruno Pereira, Christophe Bonnet, Elsa Poullot, Leticia Quintanilla-Martinez, Romain Dubois, Francisco Llamas-Gutierrez, Céline Bossard, Roland De Wind, Fanny Drieux, Juliette Fontaine, Marie Parrens, Jeremy Sandrini, Virginie Fataccioli, Marie-Hélène Delfau-Larue, Adrien Daniel, Faustine Lhomme, Lauriane Clément-Filliatre, François Lemonnier, Anne Cairoli, Pierre Morel, Sylvie Glaisner, Bertrand Joly, Abderrazak El Yamani, Kamel Laribi, Emmanuel Bachy, Reiner Siebert, David Vallois, Philippe Gaulard, Olivier Tournilhac, and Laurence De Leval

Subjects
Male, Enteropathy-Associated T-Cell Lymphoma, Mutation, Humans, Female, Genomics, Hematology, Aged, Enteropathy-Associated T-Cell Lymphoma/genetics, Enteropathy-Associated T-Cell Lymphoma/metabolism, Enteropathy-Associated T-Cell Lymphoma/pathology, Signal Transduction
Abstract

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare aggressive T-cell lymphoma most reported in Asia. We performed a comprehensive clinical, pathological and genomic study of 71 European MEITL patients (36 males, 35 females, median age 67 years). The majority presented with gastrointestinal involvement and had emergency surgery, and 40% had stage IV disease. The tumors were morphologically classified into two groups: typical (58%) and atypical (i.e., non-monomorphic or with necrosis, angiotropism or starry-sky pattern) (42%), sharing a homogeneous immunophenotypic profile (CD3+ [98%] CD4- [94%] CD5- [97%] CD7+ [97%] CD8+ [90%] CD56+ [86%] CD103+ [80%] cytotoxic marker+ [98%]) with more frequent expression of TCRgd (50%) than TCRab (32%). MYC expression (30% of cases) partly reflecting MYC gene locus alterations, correlated with non-monomorphic cytology. Almost all cases (97%) harbored deleterious mutation(s) and/or deletion of the SETD2 gene and 90% had defective H3K36 trimethylation. Other frequently mutated genes were STAT5B (57%), JAK3 (50%), TP53 (35%), JAK1 (12.5%), BCOR and ATM (11%). Both TP53 mutations and MYC expression correlated with atypical morphology. The median overall survival (OS) of 63 patients (43/63 only received chemotherapy after initial surgery) was 7.8 months. Multivariate analysis found a strong negative impact on outcome of MYC expression, TP53 mutation, STAT5B mutation and poor performance status while aberrant B-cell marker expression (20% of cases) correlated with better survival. In conclusion, MEITL is an aggressive disease with resistance to conventional therapy, predominantly characterized by driver gene alterations deregulating histone methylation and JAK/STAT signaling and encompasses genetic and morphologic variants associated with very high clinical risk.

Published
2022

2. Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases

Author

Violaine Safar, Caroline Regny, Sylvain Lamure, Alexandra Traverse-Glehen, Catherine Chassagne-Clément, Guillaume Aussedat, Pierre Hirsch, Guillaume Manson, Marie Le Cann, Emmanuelle Nicolas-Virelizier, Jean-Marie Michot, Juliette Fontaine, Patrick Tas, Aspasia Stamatoullas, Christiane Copie-Bergman, Clémentine Sarkozy, Hervé Ghesquières, Thierry Jo Molina, Richard Lemal, Jean-Michel Picquenot, Camille Laurent, Albane Ledoux-Pilon, Gilles Salles, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Adolescent, Diagnosis, Differential, Extranodal Disease, Young Adult, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, medicine, Classical Hodgkin lymphoma, Humans, Pathological, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Aged, 80 and over, Series (stratigraphy), business.industry, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, medicine.disease, Hodgkin Disease, 3. Good health, Lymphoma, Primary Mediastinal Lymphoma, 030220 oncology & carcinogenesis, Female, Clinico pathological, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, 030215 immunology
Abstract

Composite and sequential lymphomas involving both classical Hodgkin lymphoma (CHL) and primary mediastinal B-cell lymphoma (PMBCL) are rare phenomena. Beyond the relevant biological interest raised by these cases, treatments and outcome data are poorly covered in the recent literature. This retrospective analysis describes the pathological and clinical characteristics of 10 composite and 15 sequential cases included after a central pathological review. At diagnosis, 70% of the composite lymphomas presented a disseminated and extranodal disease. Among the 15 sequential lymphomas, 12 were CHL at first occurrence and three were PMBCL. Based on their clinical evolution, these sequential lymphomas could be divided into early (i.e., diagnosis of second lymphoma within a year) and late [(i.e., a second lymphoma occurrence occurring after a long period of complete remission]). All composite cases were alive in complete remission after a median follow-up of 34 months. If the early sequential lymphoma presented a particularly poor outcome with a median overall survival shorter than one year, the late cases were efficiently salvaged. Further molecular studies are needed to describe the underlying biology of these rare diseases, possibly representing the extreme of tumour cell plasticity found in grey-zone lymphoma.

Published
2020

3. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)

Author

Anne Lavaud, Audrey Bidet, Damien Roos-Weil, Benjamin Carpentier, Stéphane Leprêtre, Antoine Martin, Lauren Veronese, Alain Delmer, Loic Ysebaert, Bénédicte Hivert, Julien Broséus, Anne Corby, Eric Van Den Neste, Stéphanie Poulain, Agathe Waultier Rascalou, Kamel Laribi, Damien Luque Paz, Romain Guieze, Lise Willems, Jérôme Paillassa, Fatiha Merabet, Jean-Philippe Vial, Fanny Baran-Marszak, Pierre Feugier, Albane Ledoux-Pilon, Anne Quinquenel, Michaël Munger, Florence Cymbalista, Virginie Eclache, Eve Maubec, Chloé Friedrich, Marie-Sarah Dilhuydy, Lysiane Molina, Grégory Lazarian, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord, Hôpital de l'Enfant-Jésus [CHU Québec] (HEJ), CHU de Québec–Université Laval, Université Laval [Québec] (ULaval)-Université Laval [Québec] (ULaval), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), CRHU Nancy, Unité clinique de pathologie neuromusculaire [CHU Pitié-Salpêtrière], Institut de Myologie, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Le Mans (CH Le Mans), Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cliniques Universitaires Saint-Luc [Bruxelles], Centre Hospitalier de la Rochelle (CH la Rochelle), Centre de Biologie Pathologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Avicenne [AP-HP], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), FAYE, Fatimata, Signalisation, Microenvironnement et Hémopathies Lymphoïdes B (SIMHEL), Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-Adaptateurs de signalisation en hématologie (ASIH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Oncology, Adult, Male, medicine.medical_specialty, Skin Neoplasms, Chronic lymphocytic leukemia, Internal medicine, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Skin, Aged, 80 and over, B-Lymphocytes, business.industry, Leukemia cutis, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, 3. Good health, Leukemia, Treatment Outcome, Mutation, Female, France, medicine.symptom, business
Abstract

TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary cutaneous malignancies, as patients are at high risk of developing basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Specific cutaneous infiltration by neoplastic B lymphocytes with clinically identifiable skin lesions, also called leukemia cutis (LC), is more uncommon and has seldom been reported in chronic lymphocytic leukemia. [...]

Published
2021

4. TCL1 expression patterns in Waldenström macroglobulinemia

Author

Xavier Leleu, Nicolas Cagnard, Aurélie Ravinet, Stéphanie Poulain, Véronique Leblond, Sandrine Bard-Sorel, Romain Guieze, Olivier Tournilhac, Albane Ledoux-Pilon, Jacques-Olivier Bay, Laura Montrieul, Olivier Hermine, Pierre Dechelotte, Pierre Morel, Frédéric Charlotte, Richard Lemal, and Sébastien Bailly

Subjects
Adult, Male, 0301 basic medicine, Pathology, medicine.medical_specialty, Chronic lymphocytic leukemia, Malignancy, Pathology and Forensic Medicine, Surgical pathology, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, immune system diseases, Proto-Oncogene Proteins, hemic and lymphatic diseases, medicine, Humans, Multiple myeloma, Aged, Aged, 80 and over, B-Lymphocytes, business.industry, Waldenstrom macroglobulinemia, Anatomical pathology, Middle Aged, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Immunology, Female, Bone marrow, Waldenstrom Macroglobulinemia, business, Hematopathology
Abstract

The oncogenic role of TCL1 in chronic lymphocytic leukemia is well established in transgenic mice. TCL1 expression in other B-cell malignancies has been also described: post-germinal center-derived malignancies, such as multiple myeloma, classically do not express TCL1. Waldenström macroglobulinemia is a post-germinal center malignancy that is known to be similar to chronic lymphocytic leukemia in terms of its gene expression profile. TCL1 expression has not been so far assessed in Waldenström macroglobulinemia. Transcriptomic explorations show that TCL1A expression is linked to signaling pathways and biological functions that are known to be involved in Waldenström macroglobulinemia as well as to gene signatures of interest in B-cell malignancies. We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenström macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact. TCL1 could have an oncogenic role in Waldenström macroglobulinemia, and deserves further exploration.

Published
2016

5. Invasive Infections Caused by Nannizziopsis spp. Molds in Immunocompromised Patients

Author

Christine Jacomet, Charlotte Bothorel, Sophie Cayot, Philippe Poirier, Albane Ledoux-Pilon, Olivier Lesens, Magali Vidal-Roux, Fanny Anthony-Moumouni, Céline Nourrisson, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), CHU Clermont-Ferrand, Service d'Anatomie Pathologique [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), and Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS)-Université d'Auvergne - Clermont-Ferrand I (UdA)

Subjects
0301 basic medicine, Antifungal Agents, Epidemiology, Nannizziopsis, Biopsy, lcsh:Medicine, HIV Infections, invasive fungal infection, emerging disease, ComputingMilieux_MISCELLANEOUS, medicine.diagnostic_test, biology, Dispatch, Middle Aged, 3. Good health, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, immunocompromised patients, Female, Radiology, France, Microbiology (medical), medicine.medical_specialty, Cerebral Abscesses, 030106 microbiology, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Immunocompromised Host, central nervous system fungal infection, molds, medicine, Dermatomycoses, Humans, lcsh:RC109-216, business.industry, Arthrodermataceae, lcsh:R, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 030104 developmental biology, Tomography x ray computed, fungi, business, Tomography, X-Ray Computed, Invasive Infections Caused by Nannizziopsis spp. Molds in Immunocompromised Patients, opportunistic fungal pathogen, Biomarkers, Invasive Fungal Infections, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

We report 2 new cases of invasive infections caused by Nannizziopsis spp. molds in France. Both patients had cerebral abscesses and were immunocompromised. Both patients had recently spent time in Africa.

Published
2018

6. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

Author

Fabien Le Bras, Corinne Haioun, Richard Delarue, Laurence de Leval, Albane Ledoux-Pilon, Sylvie Thiebault, Flavie Arbion, Michel Peoc'h, Frédéric Charlotte, Marie Parrens, Gandhi Damaj, Marie-Christine Rousselet, Patrick Tas, Peggy Dartigues, Philippe Gaulard, Tony Petrella, Marie-Christine Copin, Jean-Michel Picquenot, Karine Montagne, Isabelle Soubeyran, Laurence Lamant, Georges Delsol, Christian Gisselbrecht, Thierry Jo Molina, Danielle Canioni, Olivier Tournilhac, Antoine Martin, Thérèse Rousset, Barbara Petit, Françoise Berger, Martine Patey, Bettina Fabiani, Luc Xerri, Céline Bossard, Jean-Philippe Jais, Virginie Fataccioli, Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Henri Mondor, Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hôpital avicenne, Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Service d'anatomie et cytologie pathologiques [Purpan], Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Anatomopathologie [Tours], CHRU Tours-CHU Trousseau [APHP], Service d'anatomie pathologique [CHU Necker], Centre de référence des mastocytoses, CHU Necker - Enfants Malades [AP-HP], APHP, Université Pierre et Marie Curie - Paris 6 ( UPMC ), Institut Gustave Roussy ( IGR ), Service d'anatomie et cytologie pathologiques, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Service d'Anatomo-Pathologie, Assistance publique - Hôpitaux de Paris (AP-HP), Service de Biologie, CRLCC Eugène Marquis ( CRLCC ), Service de neuropathologie, CHU Saint-Etienne, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire d'anatomie cytologie pathologiques, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Gui de Chauliac, Laboratoire HIFIH, PRES Université Nantes Angers Le Mans ( UNAM ) -IFR132-UPRES 3859, Department de pathologie cellulaire et tissulaire, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ) -PRES Université Nantes Angers Le Mans ( UNAM ), Génétique tumorale - Pathologie, CHU Bordeaux [Bordeaux]-Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Clermont-Ferrand, EA7283, CIC501, Université d'Auvergne - Clermont-Ferrand I ( UdA ), Laboratoire DIAG, GELA, Groupe d'Etude des Lymphomes de l'Adulte, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Centre de Recherche en Cancérologie de Toulouse ( CRCT ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Fédérale Toulouse Midi-Pyrénées, Centre de Physiopathologie Toulouse Purpan (ex IFR 30 et IFR 150), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR30-IFR150-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département de pathologie [Mondor], Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), CHU Henri Mondor [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Service Anatomie et cytologie pathologiques [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre de référence des mastocytoses (CEREMAST), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut Gustave Roussy (IGR), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CRLCC Eugène Marquis (CRLCC), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER-CHU Bordeaux [Bordeaux], CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT), Centre de Physiopathologie Toulouse Purpan (CPTP), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'anatomie et cytologie pathologiques [CHU Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], CHU Bordeaux [Bordeaux]-Institut Bergonié [Bordeaux], and UNICANCER-UNICANCER

Subjects
Oncology, Male, Databases, Factual, Female, France/epidemiology, Humans, Immunoblastic Lymphadenopathy/epidemiology, Immunoblastic Lymphadenopathy/pathology, Lymphoma, T-Cell/epidemiology, Lymphoma, T-Cell/pathology, medicine.medical_specialty, Angioimmunoblastic T-cell lymphoma, Lymphoma, Epidemiology, T cell, [SDV]Life Sciences [q-bio], Lymphoma, T-Cell, angioimmunoblastic T-cell lymphoma, Databases, Lymphoma t-cell, hemic and lymphatic diseases, Internal medicine, medicine, Prevalence, T-cell lymphoma, Online Only Articles, peripheral T-cell lymphoma, ComputingMilieux_MISCELLANEOUS, Factual, [ SDV ] Life Sciences [q-bio], business.industry, Cancer, Hematology, medicine.disease, T-Cell, Information data, Peripheral T-cell lymphoma, 3. Good health, medicine.anatomical_structure, Immunoblastic Lymphadenopathy, Immunology, France, business
Abstract

Reliable information regarding the current prevalence of peripheral T-cell lymphoma (PTCL) entities is missing. Herein we report on the frequency of PTCL entities in France between 2010 and 2013. Using Lymphopath , a national lymphoma network established by the French National Cancer Agency, which

Published
2015

7. Vaginal Lymphoma: A Possible Cause of Genital Hemorrhage

Author

Moluçon-Chabrot C, Kullab S, Albaut M, De Simone L, Durando X, Ledoux-Pilon A, and Nohuz E

Subjects
0301 basic medicine, lcsh:Internal medicine, medicine.medical_specialty, Vaginal Neoplasms, Vaginal B-cell lymphoma, 030105 genetics & heredity, Images in Hematology, 03 medical and health sciences, 0302 clinical medicine, Text mining, medicine, Humans, lcsh:RC31-1245, Vaginal discharge, lcsh:RC633-647.5, business.industry, Lymphoma, Non-Hodgkin, lcsh:Diseases of the blood and blood-forming organs, Hematology, Middle Aged, medicine.disease, non-Hodgkin’s lymphoma, Dermatology, Lymphoma, Genital hemorrhage, Female, Uterine Hemorrhage, Postmenopausal bleeding, business, 030217 neurology & neurosurgery
Published
2016

8. [The use of ultrasonographic 3D power Doppler to describe an ovarian Sertoli-Leydig cell tumor]

Author

B, Cotte, D, Gallot, A, Ledoux-Pilon, P, Dechelotte, C, Rivoire, M, Canis, and G, Mage

Subjects
Adult, Ovarian Neoplasms, Sertoli-Leydig Cell Tumor, Imaging, Three-Dimensional, Humans, Female, Ultrasonography, Doppler
Abstract

We report one case of unilateral ovarian Sertoli-Leydig tumor with intermediate grade and heterologous element, in a young woman with clinical and biological typical presentation. We discuss 2D and 3D ultrasonographic and doppler features.

Published
2007

9. [Solitary fibrous tumor of the orbit: an unusual cause of unilateral proptosis. Case report with a review of the literature]

Author

J-B, Dériot, A, Ledoux-Pilon, F, Pilon, A, Ravel, P, Déchelotte, D, Rigal, and F, Chiambaretta

Subjects
Exophthalmos, Humans, Orbital Neoplasms, Female, Aged
Abstract

The solitary fibrous tumor (SFT) is a spindle-cell tumor that very rarely involves the orbit. We report a new case that we compare to reports in the literature.A 72-year-old woman presented a conjunctival inflammation of the right eye developing over 5 months with progressive proptosis. Magnetic resonance imaging revealed an extraconal and homogeneous mass, which showed hypointensity on T1-weighted images and hyperintensity on T2-weighted images, without specificity. Histological examination of the lesion removed by anterior orbitotomy confirmed the diagnosis of the SFT of the orbit. The patient was doing well without recurrence after 9 months.The diagnosis of SFT is histological. It is a mesenchymal tumor. Immunohistochemically, the tumor cells are strongly positive for CD34 and vimentin.The SFT of the orbit is a very rare and generally benign tumor. It must be immunohistochemically differentiated from other spindle-cell tumors of the orbit. The treatment is a complete surgical excision, and long-term follow-up is necessary because recurrence may appear long after treatment.

Published
2006

10. [Trophoblastic gestational disease: a placental site trophoblastic tumor and an epithelioid trophoblastic tumor]

Author

Florence, Bouchet-Mishellany, Albane, Ledoux-Pilon, Claude, Darcha, and Pierre, Déchelotte

Subjects
Adult, Diagnosis, Differential, Parity, Pregnancy, Placenta, Humans, Female, Gestational Trophoblastic Disease
Abstract

Placental site trophoblastic tumor and epithelioid trophoblastic tumor are rare gestational trophoblastic tumors. They both appear in the same context and follow the same course. We report two cases in patients aged 44 and 20 years. These lesions usually affect young women with a history of multiple gestations. Clinical manifestations include vaginal bleeding, uterine mass, and moderate elevation of serum beta human chorionic gonadotrophin levels. These morphologically distinct trophoblastic proliferations usually have a favorable course if complete excision is performed.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results